News
5d
InvestorsHub on MSNTempus AI Shares Drop Following Critical Short-Seller Report from Spruce PointTempus AI (NASDAQ:TEM) saw its stock decline by 4% after short-selling firm Spruce Point Capital released a scathing report ...
Ambry Genetics was the first commercial laboratory to begin offering clinical diagnostic exome sequencing testing in 2011 3, which may bring new hope to thousands of patients and families searching ...
Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. , and a leader in clinical genomic testing, today announced the publication of a study in Genetics in Medicine, the official journal of ...
Tempus AI delivered strong Q1 results, driven by the Ambry Genetics acquisition and a major AstraZeneca contract, boosting ...
Tempus AI stock is trading at a nosebleed valuation, and despite the compelling long-term upside, it's not worth investing at ...
Seasoned diagnostics executive brings expertise in financial strategy and operational infrastructure development across ...
Researchers work in a mobile Fire-Eye laboratory in Beijing in June 2020. The labs can identify coronavirus infections, as well as decipher and analyze human DNA. (Fu Tian/China News Service/Getty ...
Philadelphia — Soon after KJ Muldoon was born in the summer of 2024, he was diagnosed with a rare genetic disorder that is fatal for about half the infants who are born with it. Until now ...
The baby's disease prevented the liver from removing ammonia Half of babies with the disease die in their first week of life The baby has already shown signs of improvement The baby's disease ...
(NewsNation) — Doctors used personal gene therapy to treat an infant with a deadly genetic disease in a medical first. KJ Muldoon was born in August of 2024, and DNA sequencing revealed he had ...
18d
Zacks Investment Research on MSNAfter 92% YTD Surge, Is Tempus AI a Buy on Trump's Executive Order?Tempus AI TEM, an innovator in artificial intelligence-based healthcare solutions, has been attracting investors' interest since its successful initial public offering in June 2024. The stock has ...
For the first time, doctors have treated a baby born with a rare, life-threatening genetic disorder with a gene-editing therapy scientists tailored to specifically repair his unique mutation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results